semaglutide weekly dose GLP-1 Medications Explained: Dosage Chart, What's New, and What to Expect — Emerson Medical Semaglutide Dosage Chart Explained: Weekly

This included remission from obesity in 15 percent of the participants given semaglutide versus just 3 percent of those taking placebo

On 10 November, Novo announced plans to invest DKK42 billion (5 billion) to upgrade its manufacturing facilities to support GLP-1 products as well as other treatments for chronic diseases

This change follows the FDAs 2025 declaration that drug shortages for these medications have been resolved

For example, Pennsylvania Medicaid covers weight loss medications, and federal employees also typically have access to coverage

Both versions have selective influence on blood glucose regulation but may have minor effects on weight loss as well with fewer side effects compared to other antidiabetic medications that can cause hypoglycemia or gastrointestinal issues